The Biggest Clinical Trial Land Grab You Didn't See Coming

Think of it like the difference between a food truck that shows up in your neighborhood versus a Michelin-star restaurant 45 minutes away. Both serve food. One meets you where you already are.

An embedded research organization takes clinical trials and plugs them directly into existing community physician practices. Your primary care doc, your gastroenterologist, your allergist: these become the trial sites. Research gets woven into routine clinical care rather than existing as a parallel universe that patients have to seek out.

The advantages are intuitive. Patients don't need extra visits. Physicians already know their patients' medical histories. Electronic health records capture the data in real time. The whole thing runs on existing infrastructure instead of requiring a separate apparatus.

FOMAT has been doing this in California for over a decade, partnering with groups like Golden Valley Health Centers (which serves more than 145,000 patients across three counties) and allergy/immunology practices in the greater LA area. The Topography Health acquisition takes this coast-to-coast.

Why Topography Was the Perfect Target

Topography Health wasn't just a collection of research sites. It built an AI platform called WaypointsOS that sifts through structured and unstructured patient data to identify trial candidates. The platform is EHR-agnostic, meaning it works regardless of what electronic records system a practice uses.

The numbers tell the story: Topography's network enrolled 35,000 patients across more than 1,500 trials, generated $450 million in research revenue, and achieved something almost unheard of in the industry: 100% physician investigator retention.

That retention stat matters enormously. Training a physician investigator takes time and money. If they bail after one trial, you've lost your investment and your community connection. Topography cracked that code by protecting physicians' time and providing operational support so research doesn't cannibalize their clinical practice.

The Consolidation Wave Is Just Getting Started

FOMAT isn't operating in a vacuum. The entire clinical trial landscape is consolidating. Sponsors are gravitating toward fewer, higher-performing site networks that can deliver patients on time and on budget. A majority of sites still manually transfer data in 2025, which tells you how much room exists for tech-enabled networks to eat market share.

The tension is real, though. Consolidation boosts efficiency but risks concentrating trials in established regions. Fewer sites can mean less geographic diversity, which undermines the whole point of reaching underserved populations. Racial and ethnic diversity in clinical trials still lags significantly.

FOMAT's bet is that embedding in community practices solves both problems simultaneously: you get the operational efficiency of a coordinated network AND the diversity that comes from meeting patients in their own neighborhoods. It's consolidation without concentration.

What This Means for Sponsors (and Patients)

For pharma and biotech sponsors, a 35-site embedded network across six states represents a one-stop shop for diverse enrollment. Instead of cobbling together relationships with dozens of independent sites (many of which will under-deliver), they can tap into a unified system with proven retention and AI-powered patient matching.

For patients, especially those in historically underserved communities, this could mean the difference between never hearing about a relevant clinical trial and having their own doctor bring it up during a routine visit. That's not a small thing when you consider that participation in a trial sometimes means access to cutting-edge treatments years before they hit the market.

The question nobody can answer yet: does making one organization this dominant in the embedded research space create a gatekeeper problem? If FOMAT controls the largest network of community-embedded trial sites, sponsors may have limited alternatives. Pricing power follows market power, and we've seen that movie before in healthcare.

For now, the industry seems to be applauding. The enrollment crisis is painful enough that any organization promising to solve it will get a warm reception. Whether FOMAT can deliver on that promise at scale, across six states and 35-plus sites, is the trillion-dollar question that only time (and enrollment data) will answer.